ArticleBioImpacts : BI2025
Protective effects of sumatriptan against optic nerve injury in rats via modulation of kynurenine pathway, oxidative stress and apoptosis.
Article in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Traumatic optic neuropathy (TON) is an acute visual dysfunction subsequent to head and neck trauma. Despite immense efforts, there is no effective treatment to minimize the damage caused by TON. Due to its anti-inflammatory and neuroprotective properties, we aimed to measure the effect of sumatriptan on optic nerve injury in rats. Methods: Bulldog forceps were used to induce optic nerve crush. Immediately after trauma, a single dose of sumatriptan was intravitreally injected and rats were just observed for 1 week. Visual evoked potential (VEP) was recorded to assess optic nerve function on days 2, 5, and 7 after optic nerve injury. Retinas were extracted seven days after trauma to assess molecular and microscopic changes. Results: Crushing force reduced cell survival, decreased the amplitude of the waves, and prolonged their latency in VEP. In contrast, sumatriptan significantly increased cell survival and shortened the latency of P2 and N2 waves. Likewise, sumatriptan significantly decreased the tissue levels of toll-like receptor 4 (TLR4), phosphorylated extracellular signal-regulated kinase (p-ERK), malondialdehyde (MDA), indole-amine 2,3-dioxygenase 1 (IDO), tumor necrosis factor α (TNF-α), interferon γ (INF-γ), and kynurenine in the retinas of rats. Conclusion: These findings suggest that sumatriptan can enhance retinal cell viability, improve optic nerve function, and decrease inflammation, possibly through attenuation of TLR4, ERK, and kynurenine signaling pathways. Thus, future clinical trials should assess the efficacy of low-dose intravitreal sumatriptan for patients with TON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.